

CS/NSE&BSE/UFR/2016-17

November 24, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Stock Code: SUVEN–EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter ended 30th Sept, 2016

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 24th November, 2016, has taken on record the Standalone Un-audited Financial Results of the Company for the quarter ended 30th September, 2016.

We are enclosing herewith the **Un-audited Financial Results for the quarter ended 30th September, 2016** along with **Limited Review Report of Statutory Auditors of the Company**.

Please find enclosed **Press Release** of our company. We request you to take these documents on your records.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**



K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7

Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30th September 2016

PART - I		Quarter Ended			Six Months Ended		Rs. In Lakhs
Sl. No.	PARTICULARS	30/09/2016 Un-audited	30/06/2016 Un-audited	30/09/2015 Un-audited	30/09/2016 Un-audited	30/09/2015 Un-audited	Previous Year Ended 31/03/2016 Un-audited
1	Income from operations						
	(a) Net sales/income from operations	11,554.97	13,322.70	11,692.97	24,877.67	21,810.23	50,028.18
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net)	11,554.97	13,322.70	11,692.97	24,877.67	21,810.23	50,028.18
2	Expenses						
	(a) Cost of materials consumed	3,406.61	3,985.98	5,131.76	7,392.59	9,000.40	17,845.37
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(885.88)	(36.77)	(1,692.51)	(922.65)	(2,716.66)	(1,205.21)
	(d) Employee benefits expense	1,201.06	1,146.96	1,090.29	2,348.02	2,027.21	4,094.43
	(e) Depreciation and amortisation expense	455.22	480.58	449.80	935.80	740.26	1,672.04
	(f) Other expenses - Manufacturing Exps	1,909.16	1,741.04	1,938.57	3,650.20	3,520.14	7,522.00
	- R & D Exps	1,465.36	1,469.01	1,506.27	2,934.37	3,099.89	6,295.09
	- Others	770.61	673.07	597.73	1,443.68	1,206.90	2,597.22
	Total expenses	8,322.14	9,459.87	9,021.91	17,782.01	16,878.14	38,820.94
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	3,232.83	3,862.83	2,671.06	7,095.66	4,932.09	11,207.24
4	Other Income	675.55	449.70	602.07	1,125.25	1,116.38	1,961.51
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	3,908.38	4,312.53	3,273.13	8,220.91	6,048.47	13,168.75
6	Finance costs	123.73	159.56	150.76	283.29	254.23	587.21
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	3,784.65	4,152.97	3,122.37	7,937.62	5,794.24	12,581.54
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	3,784.65	4,152.97	3,122.37	7,937.62	5,794.24	12,581.54
10	Tax Expenses	1,128.93	895.36	598.66	2,024.29	1,210.32	2,573.55
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	2,655.72	3,257.61	2,523.71	5,913.33	4,583.92	10,007.99
12	Extraordinary Items (net of tax expense Rs ____ Lakhs)	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	2,655.72	3,257.61	2,523.71	5,913.33	4,583.92	10,007.99
14	Share of profit / (loss) of associates*	-	-	-	-	-	-
15	Minority interest *	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	2,655.72	3,257.61	2,523.71	5,913.33	4,583.92	10,007.99
16.a	Other Comprehensive Income	(11.31)	(11.30)	(11.31)	(22.61)	(22.62)	(45.22)
16.b	Total Comprehensive Income	2,644.41	3,246.31	2,512.40	5,890.72	4,561.30	9,962.77
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						61,074.42
19.i	Earning Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.09	2.56	1.98	4.65	3.60	7.86
	b) Diluted	2.09	2.56	1.98	4.65	3.60	7.86
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	2.09	2.56	1.98	4.65	3.60	7.86
	b) Diluted	2.09	2.56	1.98	4.65	3.60	7.86

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						Rs. In Lakhs
PARTICULARS	For the Quarter Ended			For the Six Months Ended		Year Ended
	30/09/2016	30/06/2016	30/09/2015	30/09/2016	30/09/2015	31/03/2016
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited
1 SEGMENT REVENUE						
a) Manufaturing (CRAMS)	10,705.18	12,766.39	10,492.66	23,471.57	20,083.31	46,786.81
b) Services (DDDSS)	849.78	556.31	1,200.31	1,406.09	1,726.92	3,241.37
c) Research & Development	-	-	-	-	-	-
Net Sales/Income from Operations	11,554.96	13,322.70	11,692.97	24,877.66	21,810.23	50,028.18
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
a) Manufaturing (CRAMS)	4,696.59	5,596.76	3,785.85	10,293.35	7,852.48	17,391.75
b) Services (DDDSS)	503.30	258.68	817.95	761.98	1,054.74	1,982.52
c) Research & Development	(1,465.36)	(1,469.01)	(1,506.28)	(2,934.37)	(3,099.89)	(6,295.08)
TOTAL	3,734.53	4,386.43	3,097.52	8,120.96	5,807.33	13,079.19
Less: i) Interest	94.99	113.26	113.13	208.25	177.32	406.52
ii) Other Un-allocable exps net off	(145.11)	120.20	(137.98)	(24.91)	(164.23)	91.13
iii) Un-allocable Income	-	-	-	-	-	-
Total Profit Before Tax	3,784.65	4,152.97	3,122.37	7,937.62	5,794.24	12,581.54
3 SEGMENT ASSETS :						
a) Manufaturing (CRAMS)	43,759.56	43,126.18	45,139.75	43,759.56	45,139.75	43,026.99
b) Services (DDDSS)	3,598.93	3,700.16	3,946.73	3,598.93	3,946.73	3,879.73
c) Research & Development	2,504.29	2,423.33	2,582.87	2,504.29	2,582.87	2,626.80
d) Un allocated	33,044.05	30,681.23	29,173.98	33,044.05	29,173.98	27,816.55
TOTAL	82,906.83	79,930.90	80,843.33	82,906.83	80,843.33	77,350.07
SEGMENT LIABILITIES :						
a) Manufaturing (CRAMS)	8,201.56	7,764.83	8,795.50	8,201.56	8,795.50	7,860.96
b) Services (DDDSS)	400.87	322.33	484.81	400.87	484.81	336.65
c) Research & Development	1,826.23	1,590.97	2,235.78	1,826.23	2,235.78	1,683.46
d) Un allocated	684.80	617.21	686.73	684.80	686.73	548.93
TOTAL	11,113.46	10,295.34	12,202.82	11,113.46	12,202.82	10,430.00

Notes: 1) The above results were reviewed by Audit Committee and approved by the Board of Directors' Meeting held on 24th November 2016


2) Corresponding Previous period figures have been regrouped / reclassified whenever necessary.

3) The statutory auditors has reviewed the financial results for the quarter ended 30th Sept 2016. The financial results for the quarter & half-year ended 30th Sept 2015, & year ended 31st March 2016 are not subject to review or audit.

4) Reconciliation between financial results previously reported (referred to as "Previous GAAP") and Ind AS for the Quarters/Year presented as under.

	Rs. In Lakhs	
	For the Quarter Ended 30/09/2015	For the Six Months Ended 30/09/2015
Net profit under previous GAAP (After Tax)	2,472.86	4,495.93
QIP issue expenses considered for grossing up to share premium account	30.29	60.58
Transitional effect on account of fair valuation of govt loans and reclassification of actuarial loss on employee benift	29.38	42.21
Deferred tax aset due to fair valuation of Mutual funds & actuarial loss on employee benefits	(8.82)	(14.81)
Net profit under Ind AS (After Tax)	2,523.71	4,583.91
Other Comprehensive Income	(11.31)	(22.61)
Total Comprehensive Income Under Ind AS	2,512.40	4,561.30

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place: Pashamylaram

Date: 24th November, 2016

We Deliver




SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5,
Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Statement of Assets & Liabilities

(Rs. In lakhs)

	Particulars	Standalone 30/09/2016	Standalone 31/03/2016
A	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	29,788.11	30,505.64
	(b) Capital Work-in-Progress	1,685.00	719.73
	(c) Other Intangible Assets	174.18	29.70
	(d) Financial Assets		
	I. Investments	4,414.68	2,298.10
	II. Loans	2.05	1.92
	III. Other Financial Assets	550.08	482.03
	(e) Deferred tax assets (net)	667.44	497.63
	(f) Other non current assets	190.09	86.07
	Total Non-Current assets	37,471.63	34,620.82
2	Current assets		
	(a) Inventories	9,817.44	8,346.44
	(b) Financial Assets		
	I. Investments	26,846.83	5.31
	II. Trade Receivables	4,629.03	5,356.49
	III. Cash and Cash equivalents	491.78	24,011.01
	IV. Bank balances otherthan (III) above	44.33	85.02
	V. Loans	6.23	11.52
	VI. Other Financial assets	2.70	2.55
	(c) Other current tax assets(net)	3,596.86	4,910.90
	Total Current assets	45,435.20	42,729.24
	TOTAL - ASSETS	82,906.83	77,350.06
B	EQUITY AND LIABILITIES		
1	EQUITY		
	(a) Equity Share Capital	1,272.82	1,272.82
	(b) Other Equity	66,965.14	61,074.42
	Equity attributable to owners of the company	68,237.96	62,347.24
2	LIABILITIES		
	(a) Financial Liabilities		
	I. Borrowings	3,168.57	4,183.12
	(b) Provisions	239.49	239.49
	(c) Other non current liabilities	147.35	150.22
	Total non-current liabilities	3,555.41	4,572.83
3	Current liabilities		
	(a) Financial Liabilities		
	I. Borrowings	2,914.35	2,416.36
	II. Trade payables	2,745.90	3,533.11
	III Other Financial Liabilities	4,476.95	4,178.96
	(b) Provisions	349.51	274.50
	(c) Other tax liabilities (net)	597.69	-
	(d) Other current liabilities	29.06	27.06
	Total Current liabilities	11,113.46	10,429.99
	TOTAL - EQUITY AND LIABILITIES	82,906.83	77,350.06
	<p>For Suven Life Sciences Ltd</p> <p></p> <p>Venkat Jasti Chairman & CEO DIN: 00278028</p>		



Ref No.LR/08/2016-17:

LIMITED REVIEW REPORT

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED


We have reviewed the accompanying statement of unaudited financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at SDE Serene Chambers, 6th Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the period ended on 30.09.2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Ind AS compliant figures of the quarter ended 30.09.2015, half year ended 30.09.2015 and year ended 31.03.2016 have not been subjected to a limited review or audit and are based on previously published financial results as adjusted for differences arising on the transition to Indian Accounting Standards (Ind AS), which have been prepared solely based on the information compiled by the Management.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **KARVY & CO.**,
Chartered Accountants
(Firm Registration No.001757S)


(AJAYKUMAR KOSARAJU)
PARTNER
M.No.021989



Place: Hyderabad
Date: 24/11/2016

News Release

Suven Revenue growth at 13.42%; PAT up by 29.15% for the half year ended Sept, 2016

HYDERABAD, INDIA (24th November, 2016) – SUVEN LIFE SCIENCES LIMITED, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2016. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 24th November 2016 at Pashamylaram (Unit 3), Medak Dist, Telangana.

Financial Highlights for the Half year ended September' 2016:

Growth in revenue	INR 2600 Mn vs Rs 2293 Mn - up by 13.42%
Growth in PAT	INR 589 Mn vs. Rs 456 Mn - up by 29.15%
Growth in EBIDTA	INR 916 Mn vs. Rs 679 Mn - up by 34.88%

Financial Highlights for the 2nd Quarter ended September' 2016 (QoQ):

Growth in revenue	INR 1223 Mn vs Rs 1377 Mn - down by 11.20%
Growth in PAT	INR 264 Mn vs. Rs 325 Mn - down by 18.54%
Growth in EBIDTA	INR 436 Mn vs. Rs 479 Mn - down by 8.96%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 293 Mn (11.28% on revenue) for the half year ended Sept' 2016.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7

Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com